Skip to main
PGEN
PGEN logo

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen Inc is gearing up for a strategic product launch of PRGN-2012 in the second half of 2025, supported by upgraded GMP facilities aimed at enhancing manufacturing capacity, which positions the company for effective supply management at the time of launch. Management's proprietary market analysis projects significant revenue growth for PRGN-2012, estimating risk-adjusted revenues of $93 million in 2026, which could increase to approximately $969 million by 2033, demonstrating strong potential market demand. With adjustments to operational models reflecting a larger projected patient population and increased annual pricing estimates for PRGN-2012, Precigen is poised for a robust market entry and adoption, backed by strong Phase 2 data indicating a favorable outlook for the company's future revenues.

Bears say

Precigen Inc's financial performance has been adversely affected by a series of operational challenges that hinder the commercialization of its synthetic biology solutions, particularly within its Biopharmaceuticals segment. The company's reliance on external collaborators for compensation and funding has resulted in inconsistent revenue streams, which raises concerns about its ability to sustain long-term growth and profitability. Additionally, the lack of clear paths to market for many of its technologies and the competitive landscape in the biotechnology sector contribute to a negative outlook for Precigen's stock.

Precigen (PGEN) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 6 analysts, Precigen (PGEN) has a Buy consensus rating as of Jul 10, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.